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Background: Home-based robotic technologies may offer the possibility of self-directed upper limb exercise after
stroke as a means of increasing the intensity of rehabilitation treatment. The current literature has a paucity of
robotic devices that have been tested in a home environment. The aim of this research project was to evaluate
a robotic device Home-based Computer Assisted Arm Rehabilitation (hCAAR) that can be used independently at
home by stroke survivors with upper limb weakness.
Methods: hCAAR device comprises of a joystick handle moved by the weak upper limb to perform tasks on the
computer screen. The device provides assistance to the movements depending on users ability. Nineteen
participants (stroke survivors with upper limb weakness) were recruited. Outcome measures performed at
baseline (A0), at end of 8-weeks of hCAAR use (A1) and 1 month after end of hCAAR use (A2) were: Optotrak
kinematic variables, Fugl Meyer Upper Extremity motor subscale (FM-UE), Action Research Arm Test (ARAT), Medical
Research Council (MRC) and Modified Ashworth Scale (MAS), Chedoke Arm and Hand Activity Inventory (CAHAI) and
ABILHAND.
Results: Two participants were unable to use hCAAR: one due to severe paresis and the other due to personal
problems. The remaining 17 participants were able to use the device independently in their home setting. No serious
adverse events were reported. The median usage time was 433 minutes (IQR 250 – 791 min). A statistically significant
improvement was observed in the kinematic and clinical outcomes at A1. The median gain in the scores at A1 were
by: movement time 19%, path length 15% and jerk 19%, FM-UE 1 point, total MAS 1.5 point, total MRC 2 points, ARAT
3 points, CAHAI 5.5 points and ABILHAND 3 points. Three participants showed clinically significant improvement in all
the clinical outcomes.
Conclusions: The hCAAR feasibility study is the first clinical study of its kind reported in the current literature; in this
study, 17 participants used the robotic device independently for eight weeks in their own homes with minimal
supervision from healthcare professionals. Statistically significant improvements were observed in the kinematic and
clinical outcomes in the study.
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Stroke is a major public health problem with an annual
incidence estimate of 15 million people worldwide [1],
between 200 and 300 per 100,000 people in Europe [2]
and around 130,000 in the United Kingdom (UK) [3].
Globally, it is the third leading cause of mortality (after
coronary heart disease and cancer) and results in 5 mil-
lion deaths annually [4]. Stroke is the leading cause of
adult onset disability worldwide, and annually, leads to
5 million people developing long-term disability and
dependency [1,2,4]. In the UK, the estimated direct
and indirect costs of stroke care are £ 9 billion a year,
accounting for approximately 5% of the total National
Health Service (NHS) costs [3]. With a progressively
ageing population and improved stroke survival rates,
the number of survivors with disability is expected to
increase in the coming decades.
Up to 85% of survivors experience some degree of par-
esis of the upper limb at the onset [5] and only 20% to
56% of survivors regain complete functional use of the
affected upper limb in spite of therapeutic intervention
at 3 months [6-9]. Recovery of upper limb function is
generally slower and less complete than return of mobil-
ity. This is partly due to the complexity of movement re-
quired for upper limb function [10,11]. Motor recovery
has been shown to be the most influential factor in deter-
mining well-being one year after stroke [12] and hence the
emphasis of rehabilitation interventions is to improve
upper limb function and reduce long term disability [9].
Novel robotic technology can provide repetitive mean-
ingful tasks, greater intensity of practice, stimulating
and engaging environment for user and alleviate the
labour-intensive aspects of hands-on conventional ther-
apy. There are a number of complex robotic devices
like Massachusetts Institute of Technology (MIT-Manus),
Mirror Image Movement Enabler (MIME), Bi-Manu-
Track, Assisted Rehabilitation and Measurement (ARM)
Guide, ARMin, GENTLE system, intelligent Pneumatic
Arm Movement (iPAM) and others that have been devel-
oped over the last two decades to assist upper arm train-
ing in rehabilitation [13,14]. Meta-analysis studies have
observed that robotic therapy can be as effective as con-
ventional therapy in improving motor strength and func-
tional ability [15,16].
Micera et al. have put forward a simple hierarchical sys-
tem of classifying robotic devices for upper limb rehabili-
tation after stroke 1) Exoskeleton devices with greater
range of movement and complex design suited for use in
hospitals and research labs for users with severe disability
2) Operational devices which are less complex, end-
effector and suitable for use by users with moderate
disability [17]. The operational devices group can be
further sub-classified as a) Class 1 devices that have
low mechanical friction, high back-driveability, fine tunedvisco-elastic properties and high cost that can be used in
lab setting and b) Class 2 devices that have a simple mech-
anical structure, compensation of inertia/friction, no back-
drivability and low cost to be used in telerehabilitation
setting at home. In the current literature, there is a
plethora of exoskeleton and class 1 devices manufac-
tured and tested so far. However there is an obvious
paucity of class 2 devices that have been tested in
home setting. There is a clear need to explore the chal-
lenges of making low-cost home-based robots that are sim-
ple, acceptable and effective in improving arm function. The
number of people needing arm rehabilitation post-stroke is
increasing worldwide and there is growing emphasis of
moving rehabilitation resources to community-setting and
peoples homes.
The technical challenges of home-based robotic ther-
apy are to make the technology safe to be deployed and
usable in a home setting. The footprint of the device
needs to be acceptable to the patient, family and carers.
The user should be able to easily set-up and use the de-
vice without the therapist being present for each session.
The user would need access to engineering support for
technical issues and would need to be remotely super-
vised by a therapist to ensure appropriate therapy is
being delivered. The clinical challenges are many; the
technology needs to be able to match conventional
therapy principles and provide the relevant therapy to
the user. There is a risk of dehumanisation of the re-
habilitation therapy if there is little interaction with
the therapist and other patients. The therapy will need
to address personal functional needs and will need to
be tailor-made for each individual user.
There have been a few devices developed to provide
home-based robotic upper limb rehabilitation for stroke
patients. RUPERT is a wearable exoskeleton robot that
helps direct the upper limb to perform functional activities
in a three-dimensional virtual reality [18]. It has been
tested in the home setting in two chronic stroke subjects
with improvement in the accuracy and smoothness of
their movements [18]. The impact on daily activities was
not reported. The exoskeleton needs to be fitted to the
user’s upper limb by the family member or carer. The ac-
ceptability of the device needs to be tested in a larger het-
erogeneous sample of stroke subjects in a home setting.
Johnson et al. [19] developed an upper limb stroke
therapy suite (intended for home use) consisting of af-
fordable hardware platforms, such as the force-reflecting
joystick (Therajoy) and wheel (TheraDrive) working on a
customisable universal software platform (UniTherapy).
A sample of 16 chronic stroke subjects with mild to
moderate upper limb weakness tried the system; simul-
taneous EMG recording of the upper limb muscles dem-
onstrated that the robot therapy can be personalised in
terms of the muscles targeted or activated by using a
Figure 1 hCAAR device.
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the ability to accurately track movement kinematics that
can be useful to monitor progress. The system is yet to
be tested in a clinical study in a home setting.
The Java therapy system is based on wrist exercises
using a low-cost commercial force feedback joystick
connected to a customised computer program of thera-
peutic activities available on the web [20]. The system
has been designed for home use and the therapy can be
monitored remotely by a therapist using a low-cost web
camera and teleconferencing software. One stroke sur-
vivor used the system for a 12-week period and showed
improvements in movement speed and movement con-
trol. The low-cost system (estimated to cost $240 for the
joystick, upper limb rest, splint and base) received high
satisfaction scores from the user and his carer. This is yet
to be tested in a larger clinical study in the home setting.
Wood et al. have developed a simple ‘Palanca’ sliding
lever device used to play an electronic ping-pong game
on the computer and have shown improvement in the
functional abilities of four stroke subjects after using the
device [21]. This feasibility study was conducted in the
research centre and showed that the low-cost device
helped maintain high level of interest, motivation and
enjoyment in therapy. A larger scale study in the home
setting is being planned.
The Assisted Movement with Enhanced Sensation
(AMES) device provides assistance to uniaxial flexion
and extension movements of the wrist (and fingers) or
ankle joint. The device also provides vibration sensa-
tion to the antagonist muscle-stretching tendon when
the agonist muscle is performing the desired action to
provide somatosensory feedback during movement. The
device provides visual feedback on the torque exerted by
the user. A study of upper limb exercises in the home set-
ting, involving eight chronic stroke participants, showed
improvements in the strength and range of movement in
the wrist and fingers after six months of home use. The ef-
fect on functional abilities of the upper limb was not re-
ported. During the home-use period, three participants
needed additional training with EMG feedback in the re-
search laboratory as they could not generate adequate
torque to be able to use the device. The system lacks vari-
ation in tasks that can affect long-term usage (engagement
in therapy) and this needs to be explored in a larger sam-
ple of patients [22].
The purpose of this study was to test the feasibility of
stroke survivors using a low-cost restorative rehabilitation
robotic system, home-based Computer Assisted Arm
Rehabilitation (hCAAR), to undertake independent upper
limb exercises at home. The aims were to test whether a)
hCAAR could be safely used in a home setting with min-
imal supervision and b) whether using the device im-
proved upper limb movement and function.Methods
hCAAR device
The hardware components of hCAAR consist of a Per-
sonal Computer (PC) allowing interaction between the
user and the computer software (Figure 1). The interface
equipment consists of a joystick handle linked to a chas-
sis. The chassis allows the handle to move within a set
workspace relative to the user. The exercise workspace
can be adjusted physically by changing the lengths of the
robot arms, or in software by scaling the difference be-
tween the movements of the joystick to pixels on the
screen. In this study the workspace was maintained as a
constant for all users. The motion of the device is lim-
ited to a two-dimensional plane at the central attach-
ment point of the joystick.
The whole device is designed to be portable enough to
be deployed in a home setting and not to require any
additional equipment or furniture other than a chair for
the user to sit on. hCAAR consists of a base unit hous-
ing the chassis and PC (39.9 kg) with a screen and stand
(5.2 kg), the robot arm (6.8 kg) and a supporting leg
(2.6 kg). The footprint of the assembled device is 65 cm
by 95 cm and it is 120 cm high.
The interface device has a system of motors and pul-
leys that provide assistance to the motion of the joystick
handle. The mechanism is driven by motors rated to
170mNm of continuous torque, which delivers a con-
tinuous torque after gearing of 14.2 Nm at the joystick’s
shoulder and 16.41 Nm at the joystick’s elbow. This can
produce a maximal excursion of forward flexion and ex-
tension of 70° at the shoulder and 320° of flexion and ex-
tension at the elbow of the joystick. Encoders on the
motors allow tracking of the joystick handle position.
This creates a position control loop, which can be chan-
ged in real time to make the handle move to different
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controller, motor and gear system enable force feedback
from the software to guide the position of the handle.
All of the above components are covered by purpose-
built panels and set-up in a moveable trolley system.
There is an additional button switch connected to the
computer that is operated by the unaffected arm while
choosing menu items and interacting with objects when
playing the computer game (Figure 2). An emergency
stop button in the system enables the user to disconnect
the motor assistance to the joystick in case of emer-
gency. The device is purpose-built for use on one side
only so that the joystick handle is operated by affected/
impaired arm and the unaffected arm is able to operate
the switch and keypad. The unaffected arm can be used
to operate the emergency button if needed. The equip-
ment was tested for reliability and physical and electrical
safety.
The computer program includes a base “software
platform” for underlying functions and a set of activity-
based tasks that was used to direct and control the exer-
cises. The software also measures the number of hits in
the assessment exercise. The assistance levels will adjust
according to the performance in the assessment exercise.
As the user performance increases, the assistance levels
decrease by the set algorithm of the software. The
computer screen provides visual and auditory feedback
of the target location and the movement of the joy-
stick. The baseline clinical examination and computer
assessment exercise allows the initial exercise parame-
ters (duration, nature of games, game levels and assist-
ance level) to be set.Figure 2 A left-hand device being used.There are two operational modes for the device:
 Active nonassist – the movement is performed
completely by individual’s own effort with no
assistance/resistance offered by the device. This
mode is used for the assessment exercise prior to
game play.
 Active assisted bimanual mode – the individual
initiates the movement and is aided by the device
towards the goal. The joystick directed movement
on the monitor can complete the task only when
accompanied by the action of a switch device
controlled by the unaffected arm. This mode is used
during game play.
There are eight computer games that are designed to
provide arm exercises to the participant. Each game in-
volves a series of linear movements within the monitor
workspace to be performed by moving the joystick using
the affected arm. The characters have to be moved to
the target and the switch device pressed by the un-
affected arm to complete each component task within
the game. Four games have animated characters to pro-
vide more fun while performing tasks and four games do
not have the animated characters. Each game is based
on a series of movement steps on the screen. Each game
has 75 built-in levels designed to provide a hierarchical
order of difficulty in terms of the number of movement
steps and the extent of workspace used. For example
level 1 of the chase game has a small workspace of ap-
proximately 4 × 2 inches on the screen whereas level 75
has a workspace of approximately 6 × 6 inches on the
screen. The range of movement the shoulder and elbow
go through while performing level 75 is greater than the
range used in level 1. This makes the levels progressively
difficult and more challenging to the user.
Study design
This was a pilot open label cohort phase 2 clinical study
as defined by the MRC Guidelines on Complex Inter-
ventions [23] for a new restorative rehabilitation device.
The study involved 8 weeks of home arm exercise using
hCAAR for stroke survivors with residual upper limb
weakness. This was not a randomised control study, all
consented participants received the hCAAR system to
undertake home exercises in addition to their usual
treatments. The usual treatment varied between individ-
ual participants and involved treatments such as NHS
community physiotherapy, private physiotherapy or self-
exercise. The study plan is as shown in Figure 3.
The study had approvals from the National Research
Ethics Committee (NREC), local Research and Develop-
ment (R&D) department and the Medicines and Healthcare
products Regulatory Agency (MHRA). People with stroke
Figure 3 Feasibility study flow diagram.
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stroke survivors attending outpatient clinics within a
large University Hospital and a primary care trust were
screened for suitability for the study.
The inclusion criteria were a) Age more than 18 years
b) Diagnosis of ischaemic or hemorrhagic stroke at least
1 month prior to inclusion c) Residual weakness of
upper limb and d) A mimimum of some voluntary arm
movement to perform the hCAAR exercise tasks includ-
ing suitable hand grip function. Participant in a sitting
position must be able to actively move the affected hand,
rested on table, by at least 15 cm. The exclusion criteria
were a) Significant pain in the weak upper limb b) Signifi-
cant limitation in the range of motion of weak upper limb
c) Cognitive impairment affecting capacity to consent
d) Sensory impairment affecting ability to use hCAAR
system and e) Significant medical co-morbidities like
uncontrolled epilepsy. Written consent was obtained
from each participant enrolled in the study. If the par-
ticipant was able to provide fully informed consent but
was unable to sign or otherwise mark the consent
form, provision for completion of the consent form by
a family member was made.
hCAAR device was set up in the participant’s home by
the research team. The general recommendation was for
at least half an hour of exercise every day for at least five
days every week, but it was suggested to participantsthat they could use the device as much as they wanted
in the 8-week period. The participant’s usual medical
and rehabilitation treatment continued as part of routine
care and was not altered due to participation in the
study. A member of the research team contacted the
participant by telephone once every two weeks to check
participant’s progress and to discuss any queries the
participant had. At end of week 8, members of the re-
search team visited the participant’s home to retrieve
the system.
Outcome measures
We used validated outcome measures to capture quality
of arm movements and clinical/ functional effect. hCAAR
usage is reported in terms of total usage time of the device
during the 8-week period, this includes the assessment ex-
ercises, warm-up exercises and game play. Detailed user
feedback about the device and their recommendations for
future development of device were gathered by semi-
structured interviews, which are not discussed in this
paper.
Measurement of voluntary upper limb movement using
kinematic variables was undertaken while performing a
standardised reaching task similar to that reported in
current literature [24,25]. A suite of Optotrak and Optokat
systems installed in a research laboratory was used to rec-
ord kinematic variables of arm movement like movement
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comprised of a position sensor/camera mounted on roof
that captures infrared signals from the markers/diodes at-
tached to the body of the participant being tested. These
signals are sent to a system control unit that calculates the
position of marker in 3 coordinates (x,y and z) and sends
the 3D raw data of marker position to the host computer
for further analysis. The Optokat system is a standardised
seating system for the participant, comprising of a chair,
frame, starting point and target touch screen. The four
corners of the frame, seat, starting position and end point
are attached with infrared light-emitting diodes or markers.
The participant was sat in a standard position and held a
stylus in the affected arm. Markers (either single or in a
rigid body group) were attached to the participant’s trunk
and arm at standard positions: sternum, shoulder, arm,
elbow forearm and wrist.
The trial began with the stylus positioned at the start
point with the elbow angle approximately 90 degrees
and forearm in midprone/neutral position and wrist in
neutral position. An auditory signal (which corresponds
to initialisation of data collection) indicated that the par-
ticipant should start the movement. Each participant
was instructed to aim towards a light switch picture on a
touch screen quickly and accurately, with the ultimate
goal of the task to press the switch on the screen with
the stylus. On touching the target, there was a bulb
image displayed with auditory signal indicating end of
task. The first task was reaching a near-reach target
120 mm away from the start position. The second task
was a far-reach task with the target 150 mm away from
start position. Five repeated trails for each task were per-
formed and software generated kinematic data in terms
of movement time, path length and normalised jerk.
Movement Time (MT) is the time taken (in seconds) to
complete the task of reaching from start position to the
target on the screen. Path Length (PL) is the distance
(in millimetres) taken to reach the target on the screen
from the start position. Jerk is the rate of change of ac-
celeration during movement and is a measure of the
smoothness and efficiency of the movement. As jerk
varies with movement time and distance travelled dur-
ing the movement, normalising the quantity in time
and distance gives the Normalised Jerk (NJ) value. NJ
is a dimensionless number that allows movements of
different durations and lengths to be compared [26].
The Fugl Meyer - Upper Extremity subsection (FM-UE),
a measure of upper limb impairment, was used as a meas-
ure of movement ability of the affected upper limb. It is a
validated measure with 33 items and a score ranging from
0 – 66 points [27]. The measure is widely used in robotic
rehabilitation research and has good reliability and validity
in stroke population [28-30]. One of the criticisms of the
scale has been its moderate responsiveness in sub-acuteand chronic stages after stroke [31,32]. The minimal
clinically important difference (MCID) is estimated to
be 6.6 [33,34].
The Action Research Arm Test (ARAT), an outcome
measure of upper limb function, was used as a measure
to complement the FM-UE scale and measure grasp,
grip, pinch and gross movements. The 19-item scale has
a score ranging from 0 to 57. Studies have reported high
reliability and validity in stroke patients [33,35]. The
scale is more responsive than FM-UE [33] but is limited
by its high floor and ceiling effects [36]. The MCID is
estimated to be 6 [33,37].
The Modified Ashworth Scale (MAS) was used to
measure spasticity (muscle stiffness) in the paretic
upper limb. Spasticity in the shoulder abductors, ad-
ductors, flexors and extensors; elbow flexors and ex-
tensors; wrist flexors and extensors; finger flexors and
extensors was recorded. The MAS score (0–4) of all
muscles were summated to get a total MAS score that
ranged from 0 to 40 [38,39]. The MCID for total MAS
is unknown.
The Medical Research Council (MRC) scale was used
to record muscle power in different muscle groups of
paretic arm. Each of the above muscle groups was
scored on a six-point ordinal scale 0–5 and the total
MRC score ranged from 0 to 50 [40]. This method of
adding scores to give a total motor power scale has been
described in the literature [41].
The Chedoke Arm and Hand Activity Inventory (CAHAI,
version 13.0) was used to capture the functional ability in
daily activities and contribution of affected upper limb in 13
real life bilateral activities. Its score ranges between 13 and
91 [42]. It has high reliability and shown to be more respon-
sive than ARAT in stroke patients [43]. The MCID is
estimated to be 6.3 [43].
The self-reported questionnaire ABILHAND was used
to capture participant perception of performance in ac-
tual daily life activities [44]. The score ranges from 0 –
46. The MCID of the scale is yet to be researched but
based on the 10% rule can be estimated to be around 5
[45,46]. The scale has been validated based on the Rasch
model and gives a linear measure of manual ability as
well. The responses were entered in to an online com-
puter program (http://www.rehab-scales.org/abilhand-
rasch-analysis-chronic-stroke.html) that gave the score
in logits.
Assessment schedule and blinding
A baseline assessment A0 was carried out just before
home installation of the device (week 0). A post-use as-
sessment (A1) was carried out just after completion of
the 8-week usage period (week 8/9) and a final as-
sessment A2 assessment was carried out 4-weeks after
A1 (week 12/13). MS and JG/DK did the kinematic
Table 1 Demographic variables of participants
Baseline characteristics Participants (n = 17)
Mean age in years 56.4 (11.5)
Sex
Male 14
Female 3
Mean time since stroke in months 24.8 (17.8)
Type of stroke
Infarction 13
Haemorrhage 4
Side of weakness
Right dominant 9
Right non-dominant 0
Left non-dominant 8
Left dominant 0
Other deficits
Expressive dysphasia 6
Pain in affected arm 3
Visual inattention 1
Employment
Not in employment before stroke 13
Gave up employment since stroke 3
Employed 1
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scores in assessment A0. SM assessed the clinical scores
in A1 and A2. MS conducted and recorded the qualitative
feedback interviews during A1 assessment. SM was not
aware of the baseline assessment scores while assessing
participants in A1 and A2. This blinding was done to min-
imise the assessor bias of knowing scores before interven-
tion and being influenced by participant’s impressions of
the intervention.
Data analysis
The output of the Optotrak software was saved as an
Excel file that was extracted to a master Excel file. The
software provided data on movement time, peak speed,
time to peak speed, path length, path length ratio, peak
elbow angle and peak trunk angle. The best three trials
for each task (near reach or far reach) were selected
based on the shortest movement time (and selected by
path length if the movement time was the same for two
trials). The selection of the three best trials enabled the
minimising of the bias of variation in the individual initi-
ating the movement on the start command and dealing
with distractions during the command. The mean of
these three trials was calculated to give the mean vari-
able value for that assessment. Percentage changes for
A1-A0, A2-A0 and A2-A1 were calculated. The min-
imal clinically important difference (MCID) values of the
kinematic variables are not yet known in the current
literature.
FM-UE, ARAT, total MAS, total MRC, CAHAI and
ABILHAND scores were calculated adding item values
using Microsoft Excel. A1-A0, A2-A0 and A2-A1 changes
were calculated. To determine clinical significance, MCID
values of outcome measures were used if already de-
scribed in the literature. MCID is defined as the smal-
lest difference in score in the domain of interest that
patients perceive as beneficial or that would be clinic-
ally meaningful.
All the statistical analyses were carried out in Microsoft
Excel and IBM SPSS version 22 software packages. The
calculations of mean, median, SD and inter-quartile ranges
and drawing the chart figures were done in Microsoft
Excel. Non-parametric tests for calculating data signifi-
cance levels were done using SPSS. A non-parametric
Friedman’s test was used to detect the significance of the
three related samples A0, A1 and A2. If this test showed
statistical significance, a Wilcoxon post-hoc analysis was
used to test for significance between two related samples
such as A0A1, A0A2 or A1A2. The significance levels for
these tests were set at p = 0.05. SPSS was also used to do
multiple regression analyses to test the relationships be-
tween independent variables such as baseline scores, age,
time since stroke and device usage; and dependent vari-
ables such as change in outcome measures.Results
Nineteen participants were recruited to the study. After
recruitment, two participants could not use the device in
their homes and dropped out of the study. One of these
two participants had reassessed his home situation (in
view of some relatives living in his house for holiday)
and felt there was inadequate space in his house to ac-
commodate the device for the period of the study. The
other participant was unable to move the joystick to
complete computer tasks even using the full assistance
mode of the device. Hence, this participant could not
continue in the study. Seventeen participants completed
8-week home use of hCAAR. The demographic informa-
tion of these participants at the time of starting device
use is shown in Table 1.
The device was installed in various locations within
the participants’ homes both at ground floor and first
floor levels. Ten participants had the device in their liv-
ing rooms, four in their bedrooms (first floor), two in
dinning rooms and one in the conservatory. The re-
search team did not encounter any difficulties in install-
ing the device in these locations.
After installation and retraining on the user instruc-
tions, 13 participants did not experience any difficulty in
logging in and using the device independently during
the entire 8-week device-use period. Two participants
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week to log in and initialise the joystick, but were able
to play games independently once the joystick was initia-
lised. These two participants became fully independent
in using the device after one week. Two other partici-
pants required help from family members to log in and
initialise the joystick for two weeks before becoming
fully independent in the using the device.
One participant could not use the device for almost
the entire study period because of personal problems
(total usage 12 min). Three participants were unable to
use device for more than two weeks during the 8-week
period due to unexpected travel and illness. One partici-
pant had a 5-year old son who would not let the partici-
pant concentrate on game play when he was around.
This participant could use the device only at times when
the son was asleep and consequently the usage time was
affected.
No serious adverse events were observed in the study.
All clinical adverse events were managed by the clinicians
in the research team and did not need hospital admis-
sion or external clinician intervention during device-
use period. One participant had a fall (and sustained a
neck of femur fracture) after completing home-use ofTable 2 Clinical observations and adverse events
Number of
participants
Clinical observations/Clinical adverse events Actio
One Wrist pain when uses joystick for more than 10 min
particularly while playing higher-level games
Advis
sessio
streng
Three Shoulder pain. Two participants reported an increase
in shoulder pain with device usage. One of them was
noted to be sitting with back unsupported in the
chair and had excessive wrist flexion while holding
the joystick. The third participant had long-standing
shoulder pain unrelated to device usage.
All thr
syndr
on sh
exerci
again
wrist
One Injured finger with bruising while trying to stretch
fingers to hold the handle of the joystick
Advis
handl
finger
to thi
One Reported scapula becoming more prominent in
affected upper limb (has had the prominence
since stroke)
Reass
exerci
Four Could not use device as expected due to personal
problems or medical problems (such as chest
infections) unrelated to device usage
None
proble
Two Low mood. One participant due to chronic ill health
and other participant due to family member being
unwell.
Reass
One Painful thumb and index finger in the affected hand,
reported to be not related to device usage.
Found
finger
One Episodes of dizziness during study period, reported to
be unrelated to device use. Lacked motivation to use
device.
Dizzin
regula
fromdevice. This event was deemed to be unrelated to
study. This participant did need hospital admission to
manage the hip fracture. Other clinical observations
during the study period are listed in Table 2.
Device-related events
All device-related events were managed by the research
engineers in the research team (JG and ML) and did not
need any external professional engineering input. Two
joysticks needed to be changed as they became noisy
and jerky in movement. Six participants encountered
joystick calibration/initialising problems that led to them
losing track of the joystick position on the screen while
starting game play. This was resolved with a home visit
by the engineer JG and additional training on initialising
the joystick; the participants picked this up easily after
one training session at home.
Device usage time
The mean device usage time during the 8-week study
was 520 min (range 12 min – 1468 min, SD 381 min).
The median usage time was 433 minutes (IQR 250 –
791 min). One participant could not use the device be-
yond 12 min due to personal problems.ns taken Result
ed to play lower level games, reduce duration of
n, use a wrist splint and do wrist stabilising and
thening exercises.
Reduction in wrist
pain
ee participants had shoulder impingement
ome on clinical examination. They were advised
oulder strengthening and range of motion
ses. One participant was advised on sitting back
st the chair and holding joystick handle with the
in a neutral position during game play.
Shoulder pain
improved with
exercises
ed on slow stretching of fingers prior to holding
e. Also received botulinum toxin injection to
flexors as routine planned treatment unrelated
s study.
No further injury
while gripping
joystick
ured and advised on scapular stabilisation
ses.
No further worsening
of prominence
. Research team not made aware of personal
ms by the participants during the study period.
Usage improved once
medical problems
were resolved
urance. n/a
to have osteoarthritis of small joints in these
s. Advised to use topical analgesia.
Good relief of
symptoms with
topical analgesia
ess symptoms resolved with adjustment of his
r medications. Needed lot of encouragement
participant’s wife to use the device.
Needed encouragement
from wife throughout
study period
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Data were available for 17 participants who completed
8 weeks of device use. The data from two participants
were not included in the analysis as there were no as-
sessments done at one of the assessments points due to
ill health on the day. The descriptive statistics for the
remaining 15 participants are shown in Tables 3, 4, 5, 6
and 7. The kinematic scores at A1 in the far reach task
showed statistically significant changes in movement
time and path length (p < 0.05) (Table 3). The percentage
improvement in the median movement time at A1 was
by 19%, path length improved by 15% and jerk improved
by 19% (Table 4). The improvements (except path length)
were maintained at the final assessment (A2) suggesting
that the improvements were retained one month after
using the device. All the clinical score improvements at
A1 were statistically significant when compared to base-
line scores (p < 0.05) (Table 5). The average FM-UE score
in this study showed a median improvement of one point
at A1 (post-use assessment). The median increase in other
clinical scores at A1 were 3 points in the ARAT score, 5.5
points in CAHAI, 3 points in ABILHAND and 2 points in
the total MRC (Table 6). The total MAS score decreased
by 1.5 points. All the improvements were maintained
at the final assessment (A2) suggesting the gains were
retained at one-month follow-up.
Grouping of participants
The inter-quartile ranges for the kinematic and clinical
scores suggest a wide distribution of values. Therefore to
perform further analysis of the data, the participants
were divided into three groups based on the magnitude
of the observed changes (in relation to the MCID values
of the clinical measures) and the uniformity of the
changes across the different clinical measures (Table 7).
The criteria used to categorise the participants are shown
below in Table 7 (MCID values FM 7; ARAT 6; CAHAI 7Table 3 Kinematic variable scores at three assessment points
significance values
Kinematic
variable
Baseline A0 Post-use A1 Final A2
Mean (SD) Mean (SD) Mean (SD)
Near
reach
Far
reach
Near
reach
Far
reach
Near
reach
Far
reach
Movement
time
0.48 0.66 0.42 0.48 0.37 0.46
(0.20) (0.33) (0.16) (0.17) (0.11) (0.11)
Path Length 154.00 188.53 141.31 164.70 126.01 161.05
(51.42) (49.5) (39.45) (38.35) (18.28) (20.75
Normalised
Jerk
393.20 453.83 276.79 385.62 282.35 349.68
(173.01) (179.15) (114.59) (149.56) (144.82) (93.06
Movement time – in sec.
Path Length – in mm.
Normalised Jerk – no units.
n/a – not applicable.and ABILHAND 5). Kinematic variables were not consid-
ered for the categorisation, as the MCID values for kine-
matic measures are not yet established.
Although there was not a clinically significant im-
provement in the overall group in their outcome mea-
sures, three participants achieved clinically significant
improvements in all four clinical outcome measures
(FM-UE, ARAT, CAHAI and ABILHAND). An additional
eight participants improved on at least one of the
measures.
Relationships between variables and outcomes
The multiple regression analysis, using the independent
variables of age, time since stroke, device usage time and
baseline scores, and dependent variable of change in
scores, revealed no significant predictive relationships
for age, time since stroke and device usage time. The
baseline clinical scores (ABILHAND logit scores), par-
ticularly the A0 scores for far reach task, seem to be the
only variable which approached significance levels for
predictive relationship with change in scores (Pearson co-
efficient exceeding 0.50 and significance value of 0.058).
The output of regression analysis is summarised in
Table 8.
Discussion
This research provides preliminary evidence that the
hCAAR robotic device can be used safely in a home set-
ting. Most of the previous robot studies have been con-
ducted in research centres or hospitals and have had a
therapist present with the patient in each treatment ses-
sion. This is the first clinical study of its kind (excluding
clinical case studies) in the literature in which the partic-
ipants used a robotic device on their own in their homes
with minimal supervision from healthcare professionals.
The feasibility study recruited 19 participants, of
which 17 participants completed the 8 weeks of hCAAR(mean and standard deviation) and statistical
Significance Significance Significance Significance
A0A1A2 A0A1 A0A2 A1A2
Near
reach
Far
reach
Near
reach
Far
reach
Near
reach
Far
reach
Near
reach
Far
reach
0.105 0.006 n/a 0.036 n/a 0.008 n/a 0.460
0.011 0.015 0.112 0.061 0.011 0.027 0.140 0.650
)
0.038 0.091 0.069 n/a 0.023 n/a 1.000 n/a
)
Table 4 Kinematic variable scores at three assessment points and percentage change in scores (median and IQR)
Kinematic
variable
Baseline A0 Post-use A1 Final A2 A1 – A0 A2 – A0 A2 – A1
Median Median Median % change % change % change
(IQR) (IQR) (IQR) Median (IQR) Median (IQR) Median (IQR)
Near reach Far reach Near reach Far reach Near reach Far reach Near
reach
Far reach Near reach Far reach Near
reach
Far reach
Movement
time
0.43 0.53 0.41 0.44 0.33 0.44 −10 −19 −9 −20 −8 2
(0.38 – 0.51) (0.48 – 0.63) (0.32 – 0.49) (0.37 – 0.55) (0.29 – 0.43) (0.42 – 0.55) (−30.5 – 3.5) (−39.5 – -11) (−37.5 – 0.5) (−42.5 – -8.5) (−26 – 12.5) (−11 – 9.5)
Path
Length
132.85 187.12 127.80 155.95 125.66 165.94 −4 −15 −7 −11 −3 4
(122.18 – 172.03) (148.89 – 212.35) (112.83 – 154.22) (140.40 – 180.41) (111.56 – 135.50) (140.23 – 179.23) (−15 – -1) (−19.5 – -4.5) (−21 – -3.5) (−23 – -4.5) (−16 – 2.5) (−4.5 – 5)
Normalised
Jerk
370.38 447.75 258.17 388.65 233.26 363.64 −23 −19 −34 −20 −7 −7
(301.71 – 405.46) (350.22 – 488.43) (227.38 – 283.43) (289.28 – 468.57) (193.63 – 308.34) (307.53 – 391.89) (−55.5 – 1) (−29 – 4.5) (−44.5 – -21.5) (−42 – -1) (−31 – -48.5) (−23.5 – 13)
Movement time – in sec.
Path Length – in mm.
Normalised Jerk – no units.
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Table 5 Clinical outcome scores at three assessment points (mean and standard deviation) and statistical significance
values
Outcome
measure
Baseline A0 Post-use A1 Final A2 Significance Significance Significance Significance
Mean (SD) Mean (SD) Mean (SD) A0A1A2 A0A1 A0A2 A1A2
FM-UE 28.5 31.1 31.2 0.028 0.009 0.094 0.964
(9.8) (8.9) (8.7)
ARAT 26.4 30.2 31.1 0.000 0.001 0.007 0.306
(19.9) (18.9) (20.1)
CAHAI 48.8 55.3 58.8 0.000 0.001 0.002 0.050
(21.7) (20.1) (18.8)
ABILHAND 18.2 22.5 23.8 0.000 0.004 0.001 0.154
(9.3) (10.1) (8.9)
Total MAS 11.0 9.1 8.5 0.000 0.001 0.004 0.344
(5.0) (4.7) (4.5)
Total MRC 36.2 39.1 39.6 0.000 0.011 0.005 0.202
(4.6) (1.3) (1.5)
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http://www.jneuroengrehab.com/content/11/1/163home use. Two participants could not use the device
and dropped out of the study: one of them did not have
the minimal active movement required to move the joy-
stick: and the other participant could not accommodate
the device at home. This highlights that the most im-
portant prerequisites to use hCAAR are having a mini-
mum voluntary movement in the upper limb and having
a home environment suitable for device installation. The
FM-UE score can be used to predict the participant’s
ability to use hCAAR. The participant with an FM-UE
score of 6/66 could not complete the computer tasks
even with full assistance and hence had to drop out of
the study. The participant with lowest FM-UE score in
this group (12/66) was able to use the device. A FM-UETable 6 Clinical outcome scores at three assessment points an
Outcome
measure
Baseline A0 Post-use A1 Final
Median Median Med
(IQR) (IQR) (IQ
FM-UE 29 32 30
(19.5 – 36.5) (28.5 – 35.5) (28–
ARAT 23 31 33
(9.5 – 44.5) (16 – 46.5) (11.5
CAHAI 47.5 55 62
(33.3 – 65.8) (42.5 – 71.8) (48.5 –
ABILHAND 17 24 22
(11.5 – 24.5) (16.5 - 31) (18 –
Total MAS 12 9.5 7.5
(7.5 – 14.5) (5.5 – 12.5) (5.5 -
Total MRC 38 40 40
(34.5 – 39.3) (38.5 - 40) (40–score of 12 could, therefore, be reasonably considered as
the minimum score to be able to use hCAAR. This,
however, cannot be considered as the definite minimum
score for usability as there were no participants with a
baseline FM-UE score between 6/66 and 12/66 in this
study.
There were no serious adverse events during the
hCAAR study. The musculoskeletal adverse events
(shoulder pain, wrist pain) noted in this study are com-
parable to those seen in other robot studies [47]. Gen-
eral advice on the appropriate positioning of upper limb,
rest, and using the available pain-free range of move-
ments is the standard approach adopted in these studies.
These musculoskeletal problems are also encountered ind change in scores (median and inter-quartile range)
A2 A1 – A0 A2 – A0 A2 – A1
ian Median Median Median
R) (IQR) (IQR) (IQR)
1 1 0
36) (1.0 – 4.0) (−1.0 – 4.5) (−1.0 – 4.5)
3 4 0
- 49) (1.0 – 4.0) (1.0 – 5.5) (−2.0 – 2.0)
5.5 10 3
68.8) (4.3 – 8.5) (2.3 – 13.5) (0 – 6.75)
3 5 0
31.5) (1–5) (1.0 – 8.5) (−0.5 – 4.0)
−1.5 −2 −1
11) (−2.5 – -0.5) (−3.5 – -1) (−2.0 – -1.0)
2 0
40) (0 – 3.25) (1.0 - 4) (0 – 1.0)
Table 7 Categorisation of participants based on changes in scores
Group Criteria Participant ID number (n)
I MCID changes in all clinical measures FM, ARAT, CAHAI and ABILHAND 8,10 and 13 3
II MCID change in at least one of the clinical measures FM, ARAT, CAHAI or ABILHAND 1, 2, 3, 5, 9, 11, 14, 18 and 19 8
III MCID change in none of the clinical measures FM, ARAT, CAHAI or ABILHAND 4, 6, 7, 16 and 17 4
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approaches are used.
hCAAR therapy had improved arm movement and
functional ability of upper limb in this study. There was
a statistically significant (p < 0.05) improvement in the
mean clinical outcome scores at A1 and this improve-
ment was retained at final assessment A2, one month
after using the device. The improvements, did not reach
clinical significance (observed gains at A1 were below
the MCID values for the outcomes: 1 point in FM-UE; 3
points in ARAT; 5.5 points in CAHAI; and 3 points in
ABILHAND). This however was not the case when indi-
vidual participant results were analysed. Some partici-
pants did show clinically significant improvements in
their scores. Three participants had achieved clinically
significant improvement in all the four clinical scores
FM-UE, ARAT, CAHAI and ABILHAND. This suggests
that there may be participant characteristics that predict
outcome from robotic therapy. Such a differential effect
of robot therapy among the participants was also seen In
the GENTLE robot study, where a group of seven out of
the 20 chronic stroke participants showed clinically sig-
nificant improvement across all outcome measures [48].
Further work needs to determine the characteristics that
predict a favourable outcome.
The changes in outcome scores seen in the hCAAR
study are comparable to those seen in previous robot
studies. The mean improvement in FM-UE score with
hCAAR was 2.5 points; this change is similar to changes
ranging from 2.8 to 5.3 that have been reported in previ-
ous robot studies [49-54]. The median improvement in
ARAT score with hCAAR was 3 points; this is less when
compared to a 9 point change in median improvementTable 8 Regression analysis between variables and outcomes
Pearson correlations
A1 A1 A
MT-near change MT-far change ABILH.
Age 0.30 0.01 0.3
Time since stroke 0.37 0.25 0.2
Device usage - 0.11 - 0.03 0.4
A0 MT-near - 0.43 n/a n/
A0 MT-far n/a 0.36 n/
A0 ABILH. n/a n/a - 0reported in the HapticMaster robot study [55]. The mean
ABILHAND logit score improved by 0.56 with hCAAR
that is higher when compared to the observed change of
0.25 logits in the Bi-Manu-Track device study [54]. There
was a 19% reduction in mean movement time with
hCAAR whereas a 35% reduction in mean movement
time was observed in a group of participants with chronic
stroke in the BFIAMT robot study [53]. There were
modest changes in strength and spasticity with hCAAR
similar to changes reported in studies of other robotic
rehabilitation devices [52,53,56].
The hCAAR study showed statistically significant im-
provement in two functional activity-based outcome
measures CAHAI and ABILHAND in some participants.
This is contrary to findings in the systematic review of
robot studies that did not find evidence of changes in
functional activities (based on changes in the FIM score)
[15]. Two reasons could be identified for this finding;
first, CAHAI and ABILHAND are more responsive mea-
sures than the FIM motor in upper limb motor recovery;
and second, previous robot studies generally report re-
sults for the entire study cohort and do not often report
on outcome measures of each individual participant.
hCAAR seemed to be most suitable for individuals
with moderate arm weakness. This median baseline FM-
UE score of participants was 29 (range 12–43). The indi-
viduals with severe weakness might not be best suited to
use the device as suggested by the one drop-out from
the study (with an FM-UE of 6/66). Participants with
mild weakness might not find the device useful as they
need to practice complex three-dimensional functional
movements, which hCAAR is unable to provide. This
finding is supported by some other robot trials whereMultiple regression coefficients - significance
1 A1 A1 A1
change MT-near change MT-far change ABILH. change
6 0.13 0.62 0.62
7 0.24 0.81 0.55
6 0.47 0.34 0.98
a 0.19 n/a n/a
a n/a 0.82 n/a
.50 n/a n/a 0.06
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on FM-UE score) benefitted more than those with severe
weakness of the upper limb [48,50,57-61].
In the hCAAR study, among the participants with
moderate weakness, the ones with lower baselines scores
seem to have better gains from device use. The regres-
sion analysis that showed that A0 baseline ABILHAND
logit score was the only variable to approach predictive
significant relationship (p = 0.06) with change in score
value (A1-A0). A similar finding was observed in the
ARMin robotic study where gains were particularly in-
creased in participants with severe impairment at base-
line [47].
The usage time in the hCAAR study was considerably
lower than that of most previous robot studies. The mean
usage of hCAAR was 520 min (range 12 min – 1468 min)
during the 8-week period. This is lower than the usage
time reported in other studies, which involved usage
time of 900 to 2160 min spread over 4 – 12 weeks
[47,53,62-64]. It can be argued that hCAAR usage time
might have been sub-therapeutic and that could ex-
plain why no dose–response relationship was seen.
Previous robot studies have also identified that there is
no advantage of robotic therapy at a low utilisation
[15,48,65,66]. One trial comprising 9 hours [540 min]
of conventional functional retraining did not show any
benefit in chronic stroke subjects with moderate upper
limb impairment [66]. This conventional retraining study
however does not report whether a subgroup of partici-
pants showed improvement in upper limb function.
There was a lack of a significant predictive relationship
between time since stroke and the improvement in out-
comes. The mean time since stroke for the three partici-
pants who showed clinically significant improved in all
four outcome measures was 11.8 months. It is an en-
couraging finding that hCAAR therapy can lead to clin-
ically significant improvements in individuals in the
chronic stages after stroke. It was difficult to compare
the effect of hCAAR between subacute and chronic
stages after stroke as most of the participants in the
study were in the chronic stage. The hCAAR study
failed to show any predictive value of age, time since
stroke, or device usage (time) in determining the treat-
ment effect. A similar finding has also been observed
in a larger study involving 38 chronic stroke partici-
pants who used the ARMin robot for 8 weeks [47].
The authors of the ARMin trial performed a post-hoc
analysis stratified by age, hand dominance and time
since stroke and did not find any significant relation-
ships between these variables and the gains.
The improvements seen at A1 in this study are sus-
tained at the 1-month follow-up at A2. Previous robot
studies suggest that improvement in chronic subjects is
maintained for up to 3 months [22,56,67]. Robotic therapyin chronic stroke shows faster gains when compared to in-
tensive conventional physiotherapy, but only while using
the device and the gains become similar to intensive con-
ventional physiotherapy in the long term (6 months)
[47,64]. It is encouraging to find that the short- and long-
term effects of robot therapy are at least similar (if not
superior) to intensive conventional physiotherapy. The
long-term retention effects of hCAAR therapy need to
be further researched.
Most robot studies so far have involved high-cost complex
devices with therapists being involved in delivering each ses-
sion of robot therapy. The only large-scale economic ana-
lysis study involving the MIT-Manus robotic device
concluded that there was no increased cost-effectiveness
with robot therapy when compared to intensive conven-
tional therapy [68]. The cost of the robotic device was US
$ 230,750 with additional maintenance costs (US$15,000)
and cost of therapist time (US$120 for 15 min of therapist
contact time per session) [68]. The cost of the hCAAR
device is much lower (approx 5,000 GBP or US$ 8,400)
compared to this and there is no therapist time in-
volved for each session. A cost-effectiveness analysis in
comparison to conventional therapy needs to be done
in future hCAAR studies in the home setting.
Limitations
There are some limitations to hCAAR device and the
feasibility study. Firstly, hCAAR is a planar robot provid-
ing exercises only to the proximal muscles of the upper
limb. The current literature suggests that the benefits to
proximal muscles from exercises do not extend to the
distal muscles in the chronic stage of recovery. This
finding has led to the development of additional distal
modules for many robotic devices, such as MIT-Manus,
GENTLE and ARMin [47,69-72]. The ADLER, RUPERT
and ARMin devices are robotic devices that promote the
upper limb to do real world tasks [18,47,73]. However
these devices are too complex to be used in home set-
tings and use of the device needs assistance from a
helper or therapist. hCAAR was designed with home use
in mind and there was a need to keep the device as sim-
ple as possible. The provision of additional attachments/
modules would make the device bigger and more com-
plex making it less appealing for home use.
An element of bilateral therapy has been incorporated
in hCAAR; its actual contribution to motor recovery in
this study is, however, minimal. Evidence on the amount
and type of involvement of the unaffected limb in bilat-
eral therapy is lacking. Most robotic devices promoting
bilateral therapy such as MIME, BATRAC, BFIAMT,
provide symmetrical bilateral therapy and one robot
study did not show any benefit of bilateral therapy over
unilateral therapy [57]. Moreover, the criticism of this ap-
proach has been that unlike the above robots, most daily
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rical therapy using robot devices needs to explored in fu-
ture studies. Even though the bilateral therapy of hCAAR
is asymmetrical and minimal, it is difficult to establish
whether the activity of the unaffected upper limb (operat-
ing a switch) had any role in the gains observed in the
study.
There was no mandatory minimum recommended
usage time planned for this study. Even though partici-
pants were advised to use the device for at least 30 min
every day for five days a week, the device software did not
provide feedback on usage time to the participants during
the study period. Lack of such reminders could have influ-
enced device usage time in the study. Several participants
suggested that the games lacked complexity and did not
match their preferences. This could be one of the reasons
for the low device usage time when compared to other
robot studies.
The small sample of participants limits the generalisa-
tion of the results on efficacy. The aim of the feasibility
study was primarily to test whether the robot device could
be used safely in a minimally supervised home setting.
The efficacy data shows the potential for therapeutic effect
in some participants and this needs to be explored in a fu-
ture hCAAR study in a larger sample of participants.
Participants in the hCAAR study, even though they had
a wide range of impairments, did not include individuals
with significant visual field defects, severe language im-
pairments, or those with severe mobility limitations. The
selection of participants was influenced by the nature of
the study in which the participants needed to be able to
attend the research laboratory (using their own transport)
for the introduction to the device and the outcome score
assessments. Future hCAAR studies must include individ-
uals with greater disability to test usability by them. Suit-
able outcome measures need to be chosen so that they
can be completed at homes and avoid participants having
to visit the research laboratory for the assessments.
This study had a greater number of male than female
participants (14:3) and greater number of middle aged
than elderly participants. Only three participants were
above 65 years of age and only one participant was above
70 years of age. This limits the assumptions we could
make on whether hCAAR would be equally usable by fe-
males and elderly people. However, this study included
one female participant who was 81 years of age and who
had never used a computer in her life before. She needed
some supervision from family members to use hCAAR at
first but became independent thereafter and completed
the study with reasonable usage time in the 8-week period
(461 min). This example suggested that the device has the
potential for use by elderly patients.
This study lacked multiple baseline assessments to esti-
mate ongoing natural recovery. From the spontaneousrecovery studies reported by Duncan et al. we know that
the recovery pattern tends to plateau after 3 or 6 months,
depending on the severity of the stroke [74]. In this study,
most of the patients were in the chronic phase of recovery
(mean time since stroke 24.8 months; median 26 months)
and there was a definite improvement in outcomes scores
at A1 followed by a plateau or slight dip in improvement
at A2. This improvement pattern suggests that the ob-
served changes are due to hCAAR use in the intervention
period and also suggests that with the aid of rehabilitation
treatments, motor improvements can occur beyond the
6 months post-stroke period.
Conclusions
In conclusion, the hCAAR feasibility study was the first
clinical study of its kind reported in the literature; in this
study, 17 participants used the robotic device independ-
ently for eight weeks in their own homes with minimal
supervision from healthcare professionals. Statistically
significant improvements were observed in the kine-
matic and clinical outcomes in the study.
In the future, the hCAAR games could be improved
and the feedback the device provides to the user on their
results and performance needs to be developed. Internet
linkage to a remote therapist to monitor the therapy and
provide professional feedback must also be considered.
A future clinical study would need to explore the use of
hCAAR in a larger, more heterogeneous sample of par-
ticipants in the home setting. A study design comparing
the combination of conventional therapy and hCAAR
with conventional therapy alone needs to be explored. A
combination of outcome measures that span the do-
mains of the ICF framework needs to be included in any
future study.
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